膝骨关节炎治疗药物——lorecivivint
A novel drug for knee osteoarthritis:lorecivivint
陈婕 1杨军 1田娜娜 1陈媛 1广梅 1范慧君 1王红军1
作者信息
- 1. 北京泰德制药股份有限公司 创新药部,北京 100176
- 折叠
摘要
lorecivivint是一种调节Wnt通路CLK/DYRK激酶的新型小分子抑制剂,通过关节腔注射给药,治疗膝骨关节炎,目前正在美国进行Ⅲ期临床试验.已完成的临床试验结果显示,lorecivivint安全性和耐受性良好,具有缓解疼痛和改善膝关节功能的显著疗效,长期治疗可改善关节结构,是具有潜力的疾病改善型骨关节炎药物.本文就lorecivivint的基本信息、作用机制、药动学和临床研究进展等方面进行概述.
Abstract
Lorecivivint is a novel small-molecule inhibitor that modulates the Wnt pathway through CLK/DYRK kinase.It is administered through intra-articular injection for the treatment of knee osteoarthritis.Phase Ⅲ clinical trials for lorecivivint are currently underway in the United States.Completed clinical trials have demonstrated that lorecivivint has good safety and tolerability,with significant efficacy in pain relief and improvement of knee joint function.Long-term treatment has shown potential in improving joint structure,making it a promising disease-modifying osteoarthritis drug.This article provides an overview of the basic information,mechanism of action,pharmacokinetics and clinical research progress of lorecivivint.
关键词
lorecivivint/Wnt通路/CLK/DYRK激酶抑制剂/膝骨关节炎/疾病改善型骨关节炎药物Key words
lorecivivint/Wnt pathway/CLK/DYRK kinase inhibitors/knee osteoarthritis/disease-modifying osteoarthritis drug引用本文复制引用
出版年
2024
NETL
NSTL
万方数据